Is midostaurin, a specific leukemia drug, suitable for all AML patients? What tests should be done

Midostaurin is an oral multi-target tyrosine kinase inhibitor, mainly targeting FLT3 mutated acute myeloid leukemia (AML) patients. It is especially suitable for newly diagnosed FLT3 mutated adult AML patients. At the same time, it is also approved for the treatment of a variety of advanced systemic mastocytosis (SM)-related diseases, including aggressive systemic mastocytosis (ASM), systemic mastocytosis with hematological neoplasms (SM-AHN), and mast cell leukemia. Although midostaurin is highly effective, it is not suitable for all AML patients. Whether this targeted drug can be used requires specific molecular testing to determine whether it can be used.

FLT3 gene mutations are common in AML patients, especially the two forms of FLT3-ITD (internal tandem duplication) and FLT3-TKD (tyrosine kinase domain point mutation), which are one of the important molecular markers of poor prognosis of AML. Midostaurin was developed based on this mutation target and can effectively block the abnormal signaling pathway of FLT3 mutant kinase, delay tumor cell proliferation and induce apoptosis. Therefore, patients must undergo gene mutation screening, especially FLT3 mutation testing, before starting midostaurin treatment. Currently commonly used methods include PCR amplification combined sequencing, high-throughput sequencing (NGS), etc. The detection samples are mainly from peripheral blood or bone marrow. Only when it is clear that FLT3 mutation is positive, the use of midostaurin has a clear therapeutic basis.

It is worth noting that for FLT3-negative AML patients, midostaurin does not show the same efficacy, and its mechanism of action is not specific, so its use is usually not recommended. In addition, during the treatment process, electrocardiogram, liver and kidney function, and hematological indicators need to be tested regularly to evaluate the safety and tolerability of the medication. In general, midostaurin is one of the important achievements under the concept of precision medicine and is suitable for AML patients with specific gene mutation background. FLT3 gene mutation detection before treatment is a key link in formulating individualized treatment plans.

Reference materials:https://medlineplus.gov/druginfo/meds/a617033.html